Status:
COMPLETED
Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis
Lead Sponsor:
Nordic Pharma SAS
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This is a longitudinal, observational, prospective, multicentre study conducted in metropolitan France, among a representative sample of office-based or mixed practice rheumatology doctors. The aim o...
Eligibility Criteria
Inclusion
- Adult patient, ambulatory, seen in a rheumatology consultation.
- With a confirmed diagnosis of RA (ACR 1987 or ACR/EULAR 2010 criteria) receiving a disease-modifying treatment with methotrexate as a monotherapy.
- With clinical, functional, structural and/or therapeutic disease progression, for whom the rheumatologist intends to change the therapeutic treatment of the RA .
- Informed about the computer processing of their medical data and their right of access and correction.
Exclusion
- Patient not treated with methotrexate for their RA.
- Already treated with a biotherapy or receiving other synthetic DMARDs (disease-modifying antirheumatic drugs) in combination with methotrexate .
- Participating in a clinical trial in rheumatology.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
854 Patients enrolled
Trial Details
Trial ID
NCT02288520
Start Date
September 1 2014
End Date
March 1 2016
Last Update
June 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nordic Pharma
Paris, France, 75007